|
|
Post by brentie on Nov 15, 2017 13:48:41 GMT -5
Perhaps a commercial similar to one that I've seen recently for V8 juice. They have a competition where a weight lifter and a "regular guy" are getting their daily fruit and vegetable requirements. The weightlifter has to shake his concoction while the "regular guy" opens his V* and drinks it. Of course the "regular guy" wins going away. Imagine the imagery of a person loading the TS and breathing in their Afrezza put against a person who has to draw insulin into a needle, push it into a meaty spot on the their body and shooting up their dose. Better yet it might be cool to see the person with the syringe excuse themselves and disappearing from the screen and not coming back until 20-30 seconds have past. Not as long as it would take someone to excuse themselves and go to the bathroom in real time but the 20-30 seconds would be an eternity in a 60 second commercial. |
|
|
|
Post by dreamboatcruise on Nov 15, 2017 14:45:35 GMT -5
My understanding and maybe incorrect is Dexcom has exclusive rights to the G6 but the M&M and the contact lens were not Dexcoms. They also have rights to the non-invasive sometimes called the band-aid CGM which is discussed here verily.com/projects/sensors/miniaturized-gcm/ The target market for this is the T2. For some reason I thought Ondou was in the M&M mix. Hopefully we will know soon what Ondou is doing and how this shakes out. Actually what you are saying about the Libre is incorrect. The last 16 minutes are available on the sensor by minute. It then stores 15 minute chunks. The limiting factor is the Abbott reader which will probably be further hacked up for the FDA imposed 10 day limit and the 12 hour startup. If you want continuous updates and alarms use this www.ambrosiasys.com/ and get the Glimp. You can do this today and my guess is you will be able to get 17 days out of the 10 day U.S. Libre. I am planning on getting one of the first available and try it out. Now some T1s are saying all the alarming drives them crazy and they won't miss it at all. To each his own but if the sensor is running $20 a week its getting pretty affordable and ideal for performance based insurance which is coming faster and faster. The sensor pill was approved today which will pick up the velocity even more. Sensor Pill? I think he's referring to a pill that just came out that you wear a bulky receiver near your stomach and then when you swallow the pill your stomach acid activates it to send a signal to the receiver to record that you took your pill. Assuming that the small quantity of metals in this isn't bad long term, it's still quite intrusive since you have to wear a bulky receiver and would be way to costly for most pills. The trial they are running is for anti-psychotics where compliance is apparently a big problem. That's likely a very unique disease where this sort of technology might make sense. Normally a person would never put up with the receiver, nor would insurance pay for all of it, merely to track whether a dose of medicine was taken when generally people can easily come up with schemes such as a daily pill case to do that. People have already developed bluetooth enabled bottle caps and pill cases to track whether someone at least tried to take their pills, but they really haven't caught on for the general population. Most people simply don't need that level of sophistication. Though I could see those being useful for elderly patients, and at least that doesn't require costly extra steps in the pill manufacturing process, or wearing a bulky device. |
|
|
|
Post by sayhey24 on Nov 15, 2017 20:28:26 GMT -5
The sensor pill was approved Monday. The receiver is about the same as current CGMs. The big driver is performance based insurance. www.theverge.com/2017/11/14/16648166/fda-digital-pill-abilify-otsuka-proteusI had an interesting conversation today on diabetes and insurance. Diabetes is so expensive that the insurance companies are looking at all options. One is to try and get the diabetic population at 51% so they can say diabetes is normal and therefore no longer need to cover it - no joke. Maybe if we treated root cause and stopped the progress their long term costs would decrease. I know its a crazy idea. |
|
|
|
Post by boca1girl on Nov 15, 2017 21:16:24 GMT -5
The sensor pill was approved Monday. The receiver is about the same as current CGMs. The big driver is performance based insurance. www.theverge.com/2017/11/14/16648166/fda-digital-pill-abilify-otsuka-proteusI had an interesting conversation today on diabetes and insurance. Diabetes is so expensive that the insurance companies are looking at all options. One is to try and get the diabetic population at 51% so they can say diabetes is normal and therefore no longer need to cover it - no joke. Maybe if we treated root cause and stopped the progress their long term costs would decrease. I know its a crazy idea. Interesting appproach insurance companies may be taking if true, but the AMA or CDC (don’t know which) just lowered the limits to classify people with high blood pressure to 130/80 from 140/90. That puts millions more people in the high blood pressure range and therefore higher costs for insurance companies. Dr. Oz commented on the Today show that starting to treat high blood pressure at the lower pressure levels would reduce other related health care cost associated with heart disease and stroke. I would think early treatment of T2 would be analogous. I don’t see how insurance companies would get off the hook to cover T2 diabetes just because more people would have it. |
|
|
|
Post by sportsrancho on Nov 17, 2017 17:24:17 GMT -5
|
|
|
|
Post by falconquest on Nov 17, 2017 17:31:38 GMT -5
test
|
|
/production/original_573352236.gif)
